

## Business Consortium



## Mission of AABC

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the group's areas of focus, which include but are not limited to: collaborations, recognition and visibility, and knowledge and information sharing. To join the membership mailing list, please email Kira Sheinerman ([ksheinerman@diamirbio.com](mailto:ksheinerman@diamirbio.com)), co-chair; Leen Kawas ([kawas@m3bio.com](mailto:kawas@m3bio.com)), co-chair; or Jim Hendrix ([jhendrix@alz.org](mailto:jhendrix@alz.org)), facilitator.



## Welcome New Members

AABC is growing! We welcome these new members:

» **Richard Cliff – Presympto**

Presympto is an early-stage company focused on the development of a blood-based diagnostic to test asymptomatic people for Alzheimer's disease. [Read more.](#)

» **Louis Jones, Ph.D. – Kenotech Labs**

Kenotech is currently focused on developing assistive, diagnostic and therapeutic technologies to alleviate the burdens of Alzheimer's disease. [Read more.](#)

» **Maria Maccicchini, Ph.D. – QR Pharma**

QR Pharma is a specialty company founded to develop novel treatments for Alzheimer's, Parkinson's and other neurodegenerative disorders. [Read more.](#)

» **John Eastman JD, MBA – Brain Chemistry Labs**

Brain Chemistry Labs is an innovative nonprofit dedicated to following a path to cure brain diseases, including Alzheimer's, ALS and Parkinson's, through cutting-edge research. [Read more.](#)

» **Diane Van Alsyne, Ph.D. – Septa Therapeutics**

Septa Therapeutics is a biotechnology company devoted exclusively to the development of an effective treatment for Alzheimer's disease. [Read more.](#)

» **Irwin Hollander, Ph.D. – Lauren Sciences LLC**

Lauren Sciences LLC is a biotechnology company developing V-Smart® Nanomedicines for brain diseases.

» **Ryan Smith, MBA, and Adam Hanina, MBA, MPHIL, AiCure**

AiCure builds and deploys clinically validated artificial intelligence technologies to optimize patient behavior and medication adherence. [Read more.](#)

» **Carsten Jarfelt, Troy Kelly, Daniel Walton, Matthew Compton – Really**

Really detects, monitors and assesses daily function of individuals, noninvasively and continuously over time to earlier detect and objectively measure preclinical symptoms of neuropsychiatric and neuropsychological disorders, from their everyday use of language and other digital data sources. [Read more.](#)



## News from AABC Members and Growth AD Companies

## BrainBits

BrainBits has launched two new product lines:

- » Microglia product lines from rat and mouse models: Fresh microglia suspended in media and delivered overnight. [Read more.](#)
- » NbCo-Culture media: Single-step method for growing neurons and astrocytes in the same culture in a controlled manner. [Read more.](#)



## News from AABC Members and Growth AD Companies (Contd.)

### ADMdx Diagnostics, Inc (ADMdx)

- » In January, ADMdx presented findings at the Human Amyloid Imaging Meeting (HAI) regarding the quantitative effects of different PET image reconstruction methods on measured amyloid SUVR. This project was conducted in collaboration with Siemens under a grant from the Radiologic Society of North America. The results are being used as inputs to the Quantitative Imaging Biomarker Alliance amyloid profile, a guideline for data acquisition, processing and analysis to minimize technical variability.
- » In February, ADM Diagnostics successfully held an initial close on its Series A Preferred Offering. Funds are being directed toward the completion and regulatory submission of our first diagnostic product supporting detection and differentiation of dementias..
- » Work led by Dr. Lisa Mosconi and co-authored by members of ADMdx titled “Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer’s disease: a cross-sectional study of middle-aged adults from the broader New York City area,” was published in *The British Medical Journal* in March. This work shows the potential benefit of a Mediterranean type diet on brain health and on biomarkers related to Alzheimer’s. A second, related paper titled “Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults” was published in the journal *Neurology* in April.
- » ADMdx has received notification of an SBIR Phase I grant funding focused on the prediction of tau burden using MRI data and machine learning approaches.
- » The company expanded its team with regulatory, quality and software engineering resources in support of its increased development activities.
- » In July, ADMdx will present findings at the Alzheimer’s Association International Conference® (AAIC®) in Chicago:
  - » “MRI Classifiers Characterize Mild Traumatic Brain Injury in Symptomatic and Presymptomatic Stages and Differentiate from Alzheimer’s Disease Related Impairment,” a poster on July 22.
  - » “MRI, FDG, and Early Frame Amyloid Image Classifiers to Characterize and Differentiate Alzheimer’s Disease Variants and Non-AD Dementias,” an oral presentation on July 25.
- » Findings from ADMdx’s analysis of image data acquired in boxers through the Cleveland Clinic Professional Fighters Brain Health Study will be presented at the Military Health System Research Symposium in August.

### NanoSomiX, Inc (NSX)

NanoSomiX, Inc. (NSX) achieved a major accomplishment: [Its first patent was granted on May 1](#). This milestone achievement formally establishes the company’s position in the laboratory testing use of Brain Derived Exosomes (BDEs). Building toward the future, The company has another five patent families progressing through the patent system. Each patent application is designed to successively broaden coverage for the diagnostic uses of BDEs.

NanoSomiX continues to make significant advancements in isolating plasma-borne BDEs assessment of associated clinically relevant biomarkers. The company is collaborating with academic researchers and pharmaceutical companies to assist with their biomarker discovery and utilization projects. Visit [www.nanosomix.com](http://www.nanosomix.com) to learn more.



## AABC Translational Animal Models Think Tank

The AABC Translation Animal Models group, chaired by Joseph Araujo, Intervivo Solutions, and facilitated by Jim Hendrix, Alzheimer’s Association in collaboration with MODEL-AD members, have organized a think tank to understand the history of Alzheimer’s animal models, explore the current state of the science to identify the gaps and to recommend specific actions in order to develop the next generation of animal models.

The Translational Animal Models for Alzheimer’s Disease Think Tank will be held as a shoulder meeting to the Alzheimer’s Association Research Roundtable on Nov. 28-29, 2018, at the Park Hyatt Hotel, Washington D.C. AABC members are invited to attend.

The meeting agenda and list of speakers will be posted on the AABC website ([alz.org/research/for\\_researchers/partnerships/aabc](http://alz.org/research/for_researchers/partnerships/aabc)).

## Schedule of Events for Q3

### Webinar: AABC Ask the Expert – Janice Hitchcock, Ph.D., Hitchcock Regulatory Consulting, Inc.

Date/Time: Aug. 29, 2 p.m. ET.

Topic: New FDA Guidance on Early Alzheimer's Disease

[JOIN WEBEX MEETING](#)

Meeting number: 740.782.049

JOIN BY PHONE

Call-in toll-free number: 1-866.316.2054 (U.S.)

Call-in number: 1. 763.391.6884 (U.S.)

[Show global numbers](#)

## Past Events

### Webinar: AABC Ask the Expert

On June 18, Michael Levitan, MBA, managing director at the Trout Group, presented IR and PR Strategy for Emerging Alzheimer's Companies. Levitan discussed how small companies should best address questions from investors, strategic partners and other third parties regarding recent failures and major challenges in the Alzheimer's space. Slides from the webinar are available on the [AABC website](#).

## AAIC July 22-26, 2018, Chicago, USA

Congratulations to our member companies that are presenting at AAIC, we encourage fellow members to support the following presentations:

### ADMdx Diagnostics, Inc (ADMdx)

|                 |   |   |
|-----------------|---|---|
| » Poster #26546 | <b>P1-09</b> [Posters Sun] Diagnosis and Prognosis: Neuroimaging, <i>Sunday, July 22, 9:30 a.m.-4:15 p.m., McCormick Place, Hall F1</i>   | <b>P1-380</b> MRI Classifiers Characterize Mild Traumatic Brain Injury in Symptomatic and Presymptomatic Stages and Differentiate from Alzheimer's Disease Related Impairment |
| » O #26890      | <b>O4-09</b> Neuroimaging: Multimodal Imaging Biomarker Relationships, <i>Wednesday, July 25, 4:15-5:45 p.m., McCormick Place, W375 A</i> | <b>O4-09-06</b> MRI, FDG, and Early Frame Amyloid Image Classifiers to Characterize and Differentiate Alzheimer's Disease Variants and Non-AD Dementias                       |

### Intervivo Solutions

|                                    |   |   |
|------------------------------------|---|---|
| » Developing Topic, Poster # 27331 | <b>P4-17</b> [Posters Wed] Developing Topics: Poster Presentations, <i>Wednesday, July 25, 9:30 a.m.-4:15p.m., McCormick Place, Hall F1</i> | Supplementation with a Novel Lipid Extract Improves Frontal Lobe Linked Cognitive Deficits in an Aged Beagle Model of Alzheimer's Disease |
|------------------------------------|---|---|

## » AAIC July 22-26, 2018, Chicago, USA (Contd.)

### T3D

---

- » O #26159  
SESSION: O1-12 Clinical: Novel Therapeutic Approaches for Neurodegenerative Disease, *Sunday, July 22, 4:15-5:45 p.m., McCormick Place, 183*
- » PRESENTATION: O1-12-04 Effects of a PPAR Delta/Gamma Agonist, T3D-959, on Metabolic and Cognitive Functions in Mild to Moderate Alzheimer's Disease Subjects. *5-5:15 p.m., McCormick Place, 183*

### Cognosci

---

- |                 |   |   |
|-----------------|---|---|
| » Poster #25868 | <b>P3-03</b> [Posters Tues] Basic and Translational Science: Development of New Models and Analysis Methods, <i>Tuesday, July 24, 9:30 a.m.-4:15 p.m., McCormick Place, Hall - F1</i> | <b>P3-070</b> Analysis of a Sporadic Mouse Model of Alzheimer's Disease |
|-----------------|---|---|
- 

### 1. AABC In-person Meeting

Date: Monday, July 23  
Time: Noon-1:30 p.m.  
Location: Hyatt Regency McCormick Place, Grant Park B Room

### 2. AABC Invited to the AAIC's ISTAART Membership Reception

*(you must be a member of ISTAART to attend)*

Date: Monday, July 23  
Time: 6-8 p.m.  
Location: Hyatt Regency, Ballroom CDE

### 3. AABC Invited to the AAIC's Reviewer's Reception

Date: Tuesday, July 24  
Time: 7-9 p.m.  
Location: Hyatt Regency, Prairie Room

## General postings to the AABC membership

To add any general postings to future newsletters, please contact April Ross at [aqross@alz.org](mailto:aqross@alz.org).

To help us grow AABC, please continue to introduce new members and/or companies to our group. We also welcome ideas for this newsletter or events so we can better serve you. Please send your suggestions to April Ross at [aqross@alz.org](mailto:aqross@alz.org).